Abeona Therapeutics Inc


Abeona Therapeutics Inc
Profile last edited on: 2/21/2020

   Gene therapies for rare genetic diseases: potential cures for Sanfilippo syndrome types A and B
Year Founded
First SBIR Year
Latest SBIR Award
Program Status


Contact Information

4848 Lemmon Avenue
Dallas, TX 75219
  (214) 905-5100

Public Profile

Formerly known as PlasmaTech Biopharmaceuticals Inc, Abeona Therapeutics was originally trading on AMEX. Following delisting, the firm moved to OTC. The firm then issued another IPO on NASDAQ in December 2015. With technologies licensed from the Universiies of Minnnesota, Nebraska and North Carolina, Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Lead programs are adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA) in collaboration with patient advocate groups, researchers, and clinicians. The company is also developing gene therapy for juvenile Batten disease (JBD); and for Fanconi anemia (FA) disorder using a CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, it is developing rare plasma protein therapies, including SDF AlphaT (alpha-1 protease inhibitor) for inherited COPD using its proprietary Salt Diafiltration (SDFT) ethanol-free process. The company is involved in marketing MuGard, a mucoadhesive oral wound rinse for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers; and ProctiGard, a mucoadhesive oral wound rinse for the treatment of rectal mucositis and radiation proctitis.
 Synopsis: Awardee Business Condition
Year Founded First SBIR Year Date of Last Award
Employee Range VC funded? IP Holdings
Revenue Range Private/Public Exchange/Symbol :